Huatpharm, a subsidiary of Huatpharm Group, is the first pharmaceutical listed company in Anhui province (It was listed in Shenzhen Stock Exchange in 2000 and the Stock Code is 000153). Established for almost 60 years, BBCA PHARMA has successively earned a reputation of China’s Top 100 Pharmaceutical Industries for several years since 2006. Integrating R&D, manufacturing with sales,Huatpharm has developed into a national high and new tech enterprise, leading with large-volume transfusion (the annual amount is over 500 million bottles/bags) and assisting by analgesic-antipyretic, cardiovascular, antibiotic products, etc. 53 international production lines certified by GMP, its products include more than ten kinds of dosage forms and 300 varieties of drugs, involving fields of bio-pharmaceutical, chemical pharmaceutical, Chinese Herbal Medicine and APIs. Employing more than 5,000 staff, the sales income of Huatpharm has been over 3 billion.Huatpharm owns seven pharmaceutical factories, one National Pharmaceutical R&D Center, six pharmaceutical marketing companies and one pharmacy chain with more than 600 pharmacies. In which, the international business company mainly engage in exporting business of APIs and preparations, importing raw materials, equipment procurement and registration of drugs. Varieties of preparations have been registered and marketed in Myanmar, Vietnam, the Philippines, Uzbekistan, Pakistan, Nigeria, Ecuador, Cameroon and many other countries. The APIs and preparations of Huatpharm have been exported not only to developing countries and regions such as Asia, Africa and Latin America, but also to developed markets such as Europe, America, Japan and Korea.